Novo Nordisk A/ S stock (DK0062498333): Global leader in diabetes and obesity treatments

Novo Nordisk A/S continues to dominate the diabetes and obesity markets with blockbuster drugs like Ozempic and Wegovy, driving strong revenue growth amid rising global demand for weight management solutions.

Novo Nordisk A/S, the Danish pharmaceutical giant, maintains its position as a leader in diabetes care and obesity treatments. The company reported robust demand for its GLP-1 agonists, including Ozempic and Wegovy, which have transformed patient outcomes and market dynamics. Shares have shown resilience, trading at approximately 128.50 DKK on May 13, 2026 on the Copenhagen Stock Exchange, according to Nasdaq Nordic as of 05/13/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novo Nordisk A/S
• Sector/industry: Healthcare / Pharmaceuticals
• Headquarters/country: Denmark
• Core markets: North America, Europe, Asia
• Key revenue drivers: Diabetes and obesity drugs
• Home exchange/listing venue: Copenhagen (NOVO-B.CO)
• Trading currency: DKK

Novo Nordisk A/S: core business model

Novo Nordisk A/S focuses primarily on discovering, developing, and delivering innovative treatments for serious chronic diseases, with a strong emphasis on diabetes and obesity. Founded in 1923, the company has evolved into a global powerhouse, employing over 64,000 people worldwide as of its 2025 annual report published in February 2026, according to Novo Nordisk investor site as of 02/2026. Its business model revolves around a robust pipeline of biologic drugs, particularly peptides and proteins, supported by advanced manufacturing capabilities in Denmark and the US.

The company's revenue is predominantly generated from its diabetes and obesity care segment, which accounted for about 85% of total sales in recent periods. Novo Nordisk employs a direct-to-patient strategy in key markets, partnering with pharmacies and healthcare providers to ensure accessibility. This model has been key to its market leadership, with products like insulin and GLP-1 receptor agonists forming the backbone of its portfolio.

Main revenue and product drivers for Novo Nordisk A/S

Ozempic (semaglutide for diabetes) and Wegovy (semaglutide for weight loss) are the primary revenue drivers, with combined sales exceeding expectations in Q1 2026 results released April 2026. Wegovy sales surged due to expanding indications and label updates for cardiovascular benefits, as detailed in the company's Q1 2026 report as of 04/2026. These drugs benefit from strong patent protection and high barriers to entry in biologic manufacturing.

Other contributors include insulin products like Tresiba and NovoLog, which maintain steady demand in the diabetes space. Rare disease treatments, such as haemophilia therapies, add diversification, though they represent a smaller share. Growth in emerging markets, particularly Asia, supports long-term revenue expansion.

Industry trends and competitive position

The global diabetes market is projected to reach $100 billion by 2030, driven by rising prevalence linked to obesity epidemics, per IQVIA report as of 2025. Novo Nordisk holds over 30% market share in GLP-1 therapies, fending off competition from Eli Lilly's Mounjaro and emerging biosimilars. Its focus on oral formulations, like Rybelsus, positions it ahead in patient convenience.

Obesity treatments represent a massive opportunity, with Wegovy's weekly injections addressing unmet needs. Supply chain expansions in the US, including new facilities in North Carolina, aim to meet surging demand amid global shortages reported in early 2026.

Why Novo Nordisk A/S matters for US investors

Novo Nordisk A/S is highly relevant for US investors due to its dominant position in the world's largest pharmaceutical market. The US accounts for roughly 55% of its sales, fueled by Medicare coverage expansions for obesity drugs under the Inflation Reduction Act updates in 2025. ADRs trade on the NYSE (NVO), providing easy access with liquidity comparable to major US blue chips.

Exposure to US healthcare trends, including payer negotiations and telehealth integration, directly impacts performance. The company's Clayton, NC facility expansions underscore commitment to American manufacturing, potentially qualifying for domestic incentives.

Conclusion

Novo Nordisk A/S stands as a cornerstone in chronic disease management, with its GLP-1 portfolio driving sustained growth amid favorable demographics. While supply constraints and competitive pressures persist, ongoing investments in capacity and R&D bolster its outlook. US investors benefit from strong market exposure and ADR accessibility, though regulatory and pricing dynamics warrant monitoring.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.